#phase2b

  1. Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development

    By Lara Goldstein Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI ) has invested a total of $50 million in Beckley Psytech Ltd ., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions. Following the investme
  2. Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed

    By Lara Goldstein Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD ) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no additional therapeutic intervention , in Generalized Anxiety Disorder (